These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34883096)

  • 21. Impact of Polysorbate 80 Grade on the Interfacial Properties and Interfacial Stress Induced Subvisible Particle Formation in Monoclonal Antibodies.
    Vaclaw C; Merritt K; Pringle V; Whitaker N; Gokhale M; Carvalho T; Pan D; Liu Z; Bindra D; Khossravi M; Bolgar M; Volkin DB; Ogunyankin MO; Dhar P
    J Pharm Sci; 2021 Feb; 110(2):746-759. PubMed ID: 32987092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188.
    Grapentin C; Müller C; Kishore RSK; Adler M; ElBialy I; Friess W; Huwyler J; Khan TA
    J Pharm Sci; 2020 Aug; 109(8):2393-2404. PubMed ID: 32194095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Hydrophobic Tail Length Variation on Surfactant-Mediated Protein Stabilization.
    Hanson MG; Katz JS; Ma H; Putterman M; Yezer BA; Petermann O; Reineke TM
    Mol Pharm; 2020 Nov; 17(11):4302-4311. PubMed ID: 33054234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Basics of Compounding: Excipients Used in Nonsterile Compounding, Part 7: Compounding with Surfactants.
    Allen LV
    Int J Pharm Compd; 2020; 24(5):388-395. PubMed ID: 32886637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Comprehensive Scientific Survey of Excipients Used in Currently Marketed, Therapeutic Biological Drug Products.
    Rao VA; Kim JJ; Patel DS; Rains K; Estoll CR
    Pharm Res; 2020 Sep; 37(10):200. PubMed ID: 32968854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the Protein Stabilizing Capability of Surfactants Against Agitation Stress and the Underlying Mechanisms.
    Zoeller MP; Hafiz S; Marx A; Erwin N; Fricker G; Carpenter JF
    J Pharm Sci; 2022 Dec; 111(12):3261-3274. PubMed ID: 36096287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of Polysorbates.
    Castañeda Ruiz AJ; Shetab Boushehri MA; Phan T; Carle S; Garidel P; Buske J; Lamprecht A
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends on Analytical Characterization of Polysorbates and Their Degradation Products in Biopharmaceutical Formulations.
    Martos A; Koch W; Jiskoot W; Wuchner K; Winter G; Friess W; Hawe A
    J Pharm Sci; 2017 Jul; 106(7):1722-1735. PubMed ID: 28302541
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.
    Dwivedi M; Blech M; Presser I; Garidel P
    Int J Pharm; 2018 Dec; 552(1-2):422-436. PubMed ID: 30300706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the Future.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Brun VL
    J Pharm Sci; 2022 Nov; 111(11):2955-2967. PubMed ID: 36002077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polysorbate 80 controls Morphology, structure and stability of human insulin Amyloid-Like spherulites.
    Zhou X; Fennema Galparsoro D; Østergaard Madsen A; Vetri V; van de Weert M; Mørck Nielsen H; Foderà V
    J Colloid Interface Sci; 2022 Jan; 606(Pt 2):1928-1939. PubMed ID: 34695760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Putative Phospholipase B-Like 2 is Not Responsible for Polysorbate Degradation in Monoclonal Antibody Drug Products.
    Zhang S; Xiao H; Goren M; Burakov D; Chen G; Li N; Tustian A; Adams B; Mattila J; Bak H
    J Pharm Sci; 2020 Sep; 109(9):2710-2718. PubMed ID: 32534029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights into the Stabilization of Interferon Alpha by Two Surfactants Revealed by STD-NMR Spectroscopy.
    Svilenov HL; Kopp KT; Golovanov AP; Winter G; Zalar M
    J Pharm Sci; 2023 Feb; 112(2):404-410. PubMed ID: 36257338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surfactant Protection Efficacy at Surfaces Varies with the Nature of Hydrophobic Materials.
    Lefebvre G; Maze A; Alvarez-Palencia Jimenez R; Bruckert F; Filipe V; Huille S; Weidenhaupt M
    Pharm Res; 2021 Dec; 38(12):2157-2166. PubMed ID: 34904200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of Formulations of Commercially Available Antibodies.
    Strickley RG; Lambert WJ
    J Pharm Sci; 2021 Jul; 110(7):2590-2608.e56. PubMed ID: 33789155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CMC determination of nonionic surfactants in protein formulations using ultrasonic resonance technology.
    Horiuchi S; Winter G
    Eur J Pharm Biopharm; 2015 May; 92():8-14. PubMed ID: 25684280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
    Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
    Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.